BioWorld - Sunday, January 26, 2020

Neurology/Psychiatric, BioWorld MedTech
%{topic} RSS Feed RSS

1-24-Abbott-Infinity-DBS-hero.png

Abbott gets FDA nod for Infinity DBS in Parkinson’s disease, unveils positive data on Proclaim XR

January 24, 2020
By Meg Bryant
No Comments
Abbott Laboratories had a winning week, scoring U.S. FDA approval of its Infinity directional deep brain stimulation (DBS) system in treating symptoms of Parkinson’s disease not adequately managed by medication. The company also reported new data underscoring the benefits of its Proclaim XR neuromodulation system in people living with chronic pain at the North American Neuromodulation Society (NANS) conference.
Read More
Man-adding-piece-to-brain
The long and short of it

Oncogene Ras affects memory consolidation

January 21, 2020
By W. Todd Penberthy
No Comments
Remember how Ras is a frequently mutated oncogene in solid tumors? Well, it turns out Ras plays a role in those memories, too. In the Jan. 13, 2020, online issue of the Proceedings of the National Academy of Sciences, scientists at the Scripps Research Institute in Juniper, Fla., reported on the discovery that Ras signals through Raf and then Rho kinase to control whether memory is short- or long-term.
Read More
1-16-nevro-senza-omnia.png
J.P. Morgan Healthcare Conference

Nevro aims to dominate pain neurostimulation with Omnia to treat across frequencies

January 16, 2020
By Stacy Lawrence
No Comments
SAN FRANCISCO – After slowing growth starting in mid-2018 and a court battle with Boston Scientific Corp. that ended in a favorable resolution, 2019 was a much better year for pain neurostimulation player Nevro Corp., as it launched a major new product. So far, 2020 is looking up too. Its shares (NYSE:NVRO) gained 5% following a presentation at the J.P. Morgan (JPM) Healthcare Conference, where it preannounced 2019 revenues and offered 2020 guidance.
Read More
1-9-Microvention-Fred.png

Microvention scores FDA nod for new aneurysm flow diverter

January 9, 2020
By Meg Bryant
No Comments
The U.S. has granted final approval to Microvention Inc., a subsidiary of Terumo Corp. based in Aliso Viejo, Calif., for its Flow Redirection Endoluminal Device (FRED) for the treatment of brain aneurysms. The flow diverter – Microvention’s third PMA approval in less than two years – is the first in the U.S. to utilize a self-expanding, braided nitinol mesh to aid in rerouting blood flow away from the weakened area and promote occlusion.
Read More
1-9-medtronic-percept-dbs.png

Medtronic gets CE mark for DBS system that tracks brain signals, as it undergoes FDA review

January 9, 2020
By Stacy Lawrence
No Comments
Dublin-based Medtronic plc received a CE mark for its Percept PC neurostimulator to treat neurologic disorders such as Parkinson’s disease. It is the first deep brain stimulation system launched in the EU that integrates the company’s technology to sense and record brain signals, known as Brainsense. It’s intended to enable more personalized treatment driven by that data.
Read More
alzheimers-tau-neuro.png

Tau PET imaging offers the potential to predict the progress of Alzheimer’s disease

January 7, 2020
By Stacy Lawrence
No Comments
Amyloid and tau proteins are both involved in the disease pathology of Alzheimer’s disease. The diagnostic and treatment research focus has long been on amyloid, which has proven almost entirely fruitless after decades of effort. But tau is becoming better understood, as investigational tau imaging agents offer the ability to visualize its presence in the brain.
Read More

Popular Stories

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe